Xencor (NASDAQ:XNCR) Hits New 12-Month High – Should You Buy?

Xencor, Inc. (NASDAQ:XNCR)’s share price reached a new 52-week high on Monday . The stock traded as high as $28.31 and last traded at $28.4590, with a volume of 170909 shares trading hands. The stock had previously closed at $27.80.

Analyst Ratings Changes

Several research analysts recently issued reports on XNCR shares. JPMorgan Chase & Co. increased their price objective on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Monday, May 11th. Cantor Fitzgerald increased their price target on Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Royal Bank Of Canada increased their price target on Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Truist Financial decreased their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.86.

Xencor Trading Up 1.0%

The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -13.50 and a beta of 0.85. The firm has a 50-day moving average of $18.90 and a 200-day moving average of $14.45.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to analysts’ expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The firm’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.41) EPS. On average, equities research analysts anticipate that Xencor, Inc. will post -3 EPS for the current year.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its holdings in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares during the period. Allworth Financial LP acquired a new stake in Xencor during the 2nd quarter valued at approximately $55,000. E Fund Management Co. Ltd. purchased a new stake in shares of Xencor in the 2nd quarter valued at $79,000. iSAM Funds UK Ltd purchased a new stake in shares of Xencor in the 2nd quarter valued at $122,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Xencor in the third quarter worth $139,000.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.